CA-SNORKEL-AI
Snorkel AI, the data-centric AI platform company, today announced record 2022 business momentum, led by triple-digit customer growth. New customer additions included BNY Mellon, Black Swan Data, Georgetown University's Center for Security and Emerging Technology (CSET), and Pixability. Snorkel AI also added five out of the top ten US banks to its customer portfolio and expanded its roster to include a number of government agencies and Fortune 500 companies across financial services, insurance, pharma and healthcare, manufacturing and retail industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230118005384/en/
Snorkel AI Heads Into 2023 With Record Momentum and Growth (Graphic: Business Wire)
Enterprise data science and machine learning teams use Snorkel Flow, the company’s flagship AI platform powered by programmatic labeling, to accelerate AI application development by 10-100x. Organizations achieve hundreds of thousands to over million dollars in return on investment per project, and unlock net-new use cases for NLP, document processing, automation, analytics, and more blocked by manual labeling.
“The rate of progress in AI is accelerating, especially with foundation models,” said Alex Ratner, CEO and co-founder, Snorkel AI. “However, more enterprises than ever before are effectively blocked by the training data needed to adapt models for their specific use cases and production quality requirements. With our data-centric AI platform, we bridge the gap between enterprise AI and the latest innovations. Our market leadership and growth are clear indicators of the value this unlocks for our customers.”
Snorkel AI continued to innovate in 2022 by announcing the general availability of Snorkel Flow. The company also added a number of data-centric AI capabilities designed to accelerate enterprise AI development with automated labeling, efficient collaboration between data scientists and subject matter experts, and rapid, model-guided iteration.
- Data-centric Foundation Model Development: Workflows to fine-tune foundation models or large language models and use them to build smaller, specialized models deployable for complex, performance-critical enterprise use cases.
- Continuous Model Feedback: Automated model training and integrated analysis to provide near real-time guidance when developing training data.
- Cluster View: Instant creation of embedding-based clusters and auto-generated cluster labeling functions to quickly turn a massive unlabeled dataset into high-quality training data.
- New Studio: Support for a wide range data types and ML tasks such as text and document classification and extraction, PDF and conversational AI pipelines, sequence tagging, and more.
Additional 2022 highlights included:
- Expanded Partnership Ecosystem: Snorkel AI deepened partnerships across the enterprise AI ecosystem including Microsoft Azure AI Services, Google BigQuery and Vertex AI, Snowflake, Aimpoint Digital, Four Inc. and more.
- Hosted Largest Data-Centric AI Conference: Future of Data-Centric AI 2022 brought together thousands of leaders of data science and analytics teams, AI/ML practitioners, researchers, and students. The three-day event featured over 50 sessions from Apple, AstraZeneca, CIA, Capital One, Comcast, Databricks, Ford, Google, JPMorgan Chase, Meta, NVIDIA, Orange, State Farm, and more.
- Published Breakthrough Research: Snorkel AI Research published over 30 papers at NeurIPS, ICLR, ACL and more with academic partners at Brown University, Stanford University, University of Washington, and University of Wisconsin-Madison. The research team also contributed to major initiatives such as the WRENCH benchmark and BigScience advancing the state-of-the-art for data-centric AI.
- Received Industry and Analyst Recognition: Snorkel AI was named a 2022 Cool Vendor in their AI Core Technologies report and ranked in CBInsights AI 100: Most Promising AI Startups 2022. The company was also recognized by VentureBeat for their AI innovation award for Applied AI. Additionally, Snorkel AI was featured in WingVC: Top 30 Enterprise Tech and CRN: Top 10 Hottest AI Startups and Emerging Vendors lists.
About Snorkel AI
Founded by a team spun out of the Stanford AI Lab, Snorkel AI makes AI application development fast and practical by unlocking the power of machine learning without the bottleneck of manually-labeled training data. Snorkel Flow is the first data-centric AI platform powered by programmatic labeling. Backed by Addition, Greylock, GV, In-Q-Tel, Lightspeed Venture Partners and funds and accounts managed by BlackRock, the company is based in Palo Alto. For more information on Snorkel AI, please visit: https://www.snorkel.ai/ or follow @SnorkelAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005384/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom